SURG-57. AI-based quantification of tumor infiltration as a major determinant of glioblastoma recurrence and predictive modeling. Read more about SURG-57. AI-based quantification of tumor infiltration as a major determinant of glioblastoma recurrence and predictive modeling.
P07.10.B INTER-RATER AGREEMENT FROM A MULTI-NATIONAL EXPERT PANEL ON RESECTABILITY OF RECURRENT GLIOBLASTOMA: A COMPLEMENTARY POST-HOC ANALYSIS OF THE PROSPECTIVE, RANDOMIZED DIRECTOR TRIAL. Read more about P07.10.B INTER-RATER AGREEMENT FROM A MULTI-NATIONAL EXPERT PANEL ON RESECTABILITY OF RECURRENT GLIOBLASTOMA: A COMPLEMENTARY POST-HOC ANALYSIS OF THE PROSPECTIVE, RANDOMIZED DIRECTOR TRIAL.
P02.02.A IL6 UNDERLIES MICROENVIRONMENT IMMUNOSUPPRESSION AND RESISTANCE TO THERAPY IN GLIOBLASTOMA. Read more about P02.02.A IL6 UNDERLIES MICROENVIRONMENT IMMUNOSUPPRESSION AND RESISTANCE TO THERAPY IN GLIOBLASTOMA.
OS11.5.A PREOPERATIVE ASSESSMENT OF TUMOR ELOQUENCE AND RESECTABILITY: AN INTERNATIONAL SURVEY. Read more about OS11.5.A PREOPERATIVE ASSESSMENT OF TUMOR ELOQUENCE AND RESECTABILITY: AN INTERNATIONAL SURVEY.
OS08.6.A A PROGNOSTIC CLASSIFICATION SYSTEM FOR EXTENT OF RESECTION IN IDH-MUTANT GRADE 2 GLIOMA: A REPORT BY THE RANO RESECT GROUP. Read more about OS08.6.A A PROGNOSTIC CLASSIFICATION SYSTEM FOR EXTENT OF RESECTION IN IDH-MUTANT GRADE 2 GLIOMA: A REPORT BY THE RANO RESECT GROUP.
JS09.5.A SPATIAL TRANSCRIPTOMIC AND ELECTRODIAGNOSTIC PROFILING REVEALS SYNAPTIC CONNECTIVITY IS A HALLMARK OF OLIGODENDROGLIOMA RECURRENCE AND MALIGNANT TRANSFORMATION. Read more about JS09.5.A SPATIAL TRANSCRIPTOMIC AND ELECTRODIAGNOSTIC PROFILING REVEALS SYNAPTIC CONNECTIVITY IS A HALLMARK OF OLIGODENDROGLIOMA RECURRENCE AND MALIGNANT TRANSFORMATION.
P13.01.B THE NATURAL HISTORY AND MOLECULAR ARCHITECTURE OF INCIDENTAL MENINGIOMAS. Read more about P13.01.B THE NATURAL HISTORY AND MOLECULAR ARCHITECTURE OF INCIDENTAL MENINGIOMAS.
OS13.7.A GENOMIC PROFILING OF 1,104 CONSECUTIVE, PROSPECTIVE MENINGIOMAS DEFINES THE POPULATION PREVALENCE OF MOLECULAR ALTERATIONS AND ELUCIDATES POTENTIAL BIOMARKERS OF TREATMENT RESPONSE. Read more about OS13.7.A GENOMIC PROFILING OF 1,104 CONSECUTIVE, PROSPECTIVE MENINGIOMAS DEFINES THE POPULATION PREVALENCE OF MOLECULAR ALTERATIONS AND ELUCIDATES POTENTIAL BIOMARKERS OF TREATMENT RESPONSE.
Salvage therapies for first relapse of SHH medulloblastoma in early childhood. Read more about Salvage therapies for first relapse of SHH medulloblastoma in early childhood.
Celebrating 30 years of the Society for NeuroOncology and its tremendous impact on the Journal. Read more about Celebrating 30 years of the Society for NeuroOncology and its tremendous impact on the Journal.
